Skip to main content

Drug Interactions between De-Sone LA and tadalafil

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

dexAMETHasone tadalafil

Applies to: De-Sone LA (dexamethasone) and tadalafil

MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tadalafil, which is primarily metabolized by the isoenzyme. Rifampin (600 mg daily), a potent CYP450 3A4 inducer, has been reported to decrease tadalafil peak plasma concentration (Cmax) and systemic exposure (AUC) from a single 10 mg dose by 46% and 88%, respectively, compared to administration of the drug alone.

MANAGEMENT: Caution is advised if tadalafil is prescribed with CYP450 3A4 inducers. For the treatment of benign prostatic hyperplasia and erectile dysfunction, no dosage adjustment of tadalafil is warranted during coadministration with CYP450 3A4 inducers. However, the possibility of diminished pharmacologic effects of tadalafil should be considered. For the treatment of pulmonary arterial hypertension, concomitant use of tadalafil with patients on chronic potent CYP450 3A4 inducer therapy is not recommended. The manufacturer of the combination therapy macitentan-tadalafil (Opsynvi), also advises against their concomitant use.

References (7)
  1. (2024) "Product Information. Opsynvi (macitentan-tadalafil)." Actelion Pharmaceuticals US Inc
  2. (2023) "Product Information. Adcirca (tadalafil)." Eli Lilly and Company Ltd
  3. (2024) "Product Information. Opsynvi 10/40 (macitentan-tadalafil)." Janssen-Cilag Pty Ltd
  4. (2025) "Product Information. Opsynvi (macitentan-tadalafil)." Janssen Inc
  5. (2019) "Product Information. Tadalafil (tadalafil)." Amneal Pharmaceuticals LLC
  6. (2021) "Product Information. Ach-Tadalafil (tadalafil)." Accord Healthcare Inc
  7. (2024) "Product Information. Cialis (tadalafil)." Eli Lilly Australia Pty Ltd

Drug and food interactions

Moderate

tadalafil food

Applies to: tadalafil

GENERALLY AVOID: Coadministration with grapefruit juice is likely to increase the plasma concentrations of tadalafil, which is primarily metabolized by CYP450 3A4. However, the interaction has not been studied. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.

MONITOR: Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors such as tadalafil are used with alcohol, as both are mild systemic vasodilators. In clinical pharmacology studies, more subjects administered alcohol at a dose of 0.7 g/kg (equivalent to approximately 6 ounces of 80-proof vodka in an 80-kg male; consumed within 10 minutes in study subjects, providing blood alcohol levels of 0.08%) in combination with tadalafil 10 or 20 mg single doses had clinically significant decreases in blood pressure than with alcohol alone. There were reports of postural dizziness, and orthostatic hypotension was observed in some. When tadalafil 20 mg was administered with alcohol at a lower dose of 0.6 g/kg (equivalent to approximately 4 ounces of 80-proof vodka in an 80-kg male), orthostatic hypotension was not observed, dizziness occurred with similar frequency relative to alcohol alone, and the hypotensive effects of alcohol were not potentiated. Neither tadalafil nor alcohol affected the plasma concentrations of the other.

MANAGEMENT: Caution is recommended with concurrent consumption of large amounts of alcohol in patients taking tadalafil as it may increase the potential for orthostatic signs and symptoms, such as increase in heart rate, decrease in standing blood pressure, dizziness, and headache. It may also be appropriate to avoid consuming large amounts of grapefruit juice.

References (8)
  1. (2009) "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation
  2. (2024) "Product Information. Opsynvi (macitentan-tadalafil)." Actelion Pharmaceuticals US Inc
  3. (2023) "Product Information. Adcirca (tadalafil)." Eli Lilly and Company Ltd
  4. (2024) "Product Information. Opsynvi 10/40 (macitentan-tadalafil)." Janssen-Cilag Pty Ltd
  5. (2025) "Product Information. Opsynvi (macitentan-tadalafil)." Janssen Inc
  6. (2019) "Product Information. Tadalafil (tadalafil)." Amneal Pharmaceuticals LLC
  7. (2021) "Product Information. Ach-Tadalafil (tadalafil)." Accord Healthcare Inc
  8. (2024) "Product Information. Cialis (tadalafil)." Eli Lilly Australia Pty Ltd

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.